Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | ATP4A | P20648 | 1/20 | 0.38 |
| ▸ | ATP4B | P51164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31517865 | 0.83 | HTT (0.49) | SMN1; SMN2HTTSTAT3L3MBTL1MAPT | |
| SCHEMBL26601861 | 0.82 | PTGDR2 (0.49) | SMN1; SMN2HTTSTAT3L3MBTL1MAPT | |
| SCHEMBL31517915 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2HTTSTAT3L3MBTL1MAPT | |
| SCHEMBL31517925 | 0.81 | HTT (0.47) | SMN1; SMN2HTTSTAT3L3MBTL1MAPT | |
| SCHEMBL26601750 | 0.80 | PTGER1 (0.45) | SMN1; SMN2HTTSTAT3MCL1PTGER1 | |
| SCHEMBL26601670 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTSTAT3L3MBTL1MAPT | |
| SCHEMBL30624528 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTSTAT3L3MBTL1MAPT | |
| SCHEMBL4781292 | 0.79 | HTT (0.54) | SMN1; SMN2HTTSTAT3L3MBTL1MAPT | |
| SCHEMBL26601820 | 0.79 | HTT (0.54) | SMN1; SMN2HTTSTAT3L3MBTL1MAPT | |
| SCHEMBL31747854 | 0.79 | CCR5 (0.50) | SMN1; SMN2HTTSTAT3L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| CN-119546580-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4511117-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511115-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | SMN1; SMN2 738/4885HTT 2180/4885STAT3 4427/4885 |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN1B, CLIC1, HCN1 | SMN1; SMN2 760/4885HTT 1485/4885STAT3 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.